Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Other Working Capital Changes (2016 - 2025)

Kiora Pharmaceuticals' Other Working Capital Changes history spans 11 years, with the latest figure at -$1.2 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 2514.68% year-over-year to -$1.2 million; the TTM value through Dec 2025 reached $34172.0, up 173.49%, while the annual FY2025 figure was $34172.0, 173.49% up from the prior year.
  • Other Working Capital Changes reached -$1.2 million in Q4 2025 per KPRX's latest filing, down from $1.7 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $1.7 million in Q3 2025 to a low of -$1.2 million in Q4 2025.
  • Average Other Working Capital Changes over 5 years is $11823.0, with a median of $6818.0 recorded in 2022.
  • Peak YoY movement for Other Working Capital Changes: surged 1722.95% in 2022, then tumbled 3496.02% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at $119403.0 in 2021, then crashed by 94.29% to $6818.0 in 2022, then skyrocketed by 1285.24% to $94446.0 in 2023, then tumbled by 149.23% to -$46500.0 in 2024, then tumbled by 2514.68% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Other Working Capital Changes are -$1.2 million (Q4 2025), $1.7 million (Q3 2025), and $14400.0 (Q2 2025).